# Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64565111 in Type 2 Diabetes Mellitus (T2DM)

> **NCT02862431** · PHASE1 · TERMINATED · sponsor: **Janssen Research & Development, LLC** · enrollment: 24 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** JNJ-64565111
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02862431
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-07-12
- **Primary completion:** 2016-11-29
- **Final completion:** 2016-12-05
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** manufacturing-related issues
- **Last updated:** 2025-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02862431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02862431, "Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64565111 in Type 2 Diabetes Mellitus (T2DM)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02862431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*